Anika Therapeutics ANIK Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's cash provided by (used in) operating activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's cash provided by (used in) operating activity, including discontinued operation?
- Anika Therapeutics (ANIK) reported cash provided by (used in) operating activity, including discontinued operation of -$684K in Q2 2026.
- How has Anika Therapeutics's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
- Anika Therapeutics's cash provided by (used in) operating activity, including discontinued operation decreased by 261.9% year-over-year, from -$189K to -$684K.
- What is the long-term trend for Anika Therapeutics's cash provided by (used in) operating activity, including discontinued operation?
- Over 3 years (2021 to 2025), Anika Therapeutics's cash provided by (used in) operating activity, including discontinued operation has grown at a 10.0% compound annual growth rate (CAGR), from $8.4M to $11.19M.
- What does cash provided by (used in) operating activity, including discontinued operation mean?
- Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.